BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 10223569)

  • 21. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
    Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
    Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
    Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
    Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
    Ji M; Jang S; Lee JH; Seo EJ
    Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
    [No Abstract]   [Full Text] [Related]  

  • 24. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma.
    Tucker CA; Bebb G; Klasa RJ; Chhanabhai M; Lestou V; Horsman DE; Gascoyne RD; Wiestner A; Masin D; Bally M; Williams ME
    Leuk Res; 2006 Apr; 30(4):449-57. PubMed ID: 16183118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).
    Kobayashi H; Saito H; Kitano K; Kiyosawa K; Gaun S; Aoki K; Narita A; Watanabe M; Uchimaru K; Motokura T
    Acta Haematol; 1995; 94(4):199-203. PubMed ID: 8610478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
    Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
    Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.
    Katayama Y; Sakai A; Okikawa Y; Oue N; Asaoku H; Sasaki A; Imanaka F; Tsujimoto T; Takimoto Y; Masuda R; Nakaju N; Otsuki T; Yasui W; Kimura A
    Int J Oncol; 2004 Sep; 25(3):579-95. PubMed ID: 15289859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.
    Specht K; Haralambieva E; Bink K; Kremer M; Mandl-Weber S; Koch I; Tomer R; Hofler H; Schuuring E; Kluin PM; Fend F; Quintanilla-Martinez L
    Blood; 2004 Aug; 104(4):1120-6. PubMed ID: 15090460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
    Wilson CS; Butch AW; Lai R; Medeiros LJ; Sawyer JR; Barlogie B; McCourty A; Kelly K; Brynes RK
    Br J Haematol; 2001 Mar; 112(3):776-82. PubMed ID: 11260083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements.
    Juskevicius D; Ruiz C; Dirnhofer S; Tzankov A
    Am J Surg Pathol; 2014 May; 38(5):719-27. PubMed ID: 24722063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathogenesis of mantle cell lymphoma.
    Jares P; Colomer D; Campo E
    J Clin Invest; 2012 Oct; 122(10):3416-23. PubMed ID: 23023712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32).
    De Angeli C; Gandini D; Cuneo A; Moretti S; Bigoni R; Roberti MG; Bardi A; Castoldi GL; del Senno L
    Haematologica; 2000 Sep; 85(9):913-21. PubMed ID: 10980628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
    Krämer A; Schultheis B; Bergmann J; Willer A; Hegenbart U; Ho AD; Goldschmidt H; Hehlmann R
    Leukemia; 2002 Sep; 16(9):1844-51. PubMed ID: 12200702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
    Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
    J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.
    Narita T; Inagaki A; Kobayashi T; Kuroda Y; Fukushima T; Nezu M; Fuchida S; Sakai H; Sekiguchi N; Sugiura I; Maeda Y; Takamatsu H; Tsukamoto N; Maruyama D; Kubota Y; Kojima M; Sunami K; Ono T; Ri M; Tobinai K; Iida S
    Blood Cancer J; 2015 Feb; 5(2):e285. PubMed ID: 25723856
    [No Abstract]   [Full Text] [Related]  

  • 36. Complex analysis of cyclin D1 expression in mantle cell lymphoma: two cyclin D1-negative cases detected.
    Stefancikova L; Moulis M; Fabian P; Falkova I; Vasova I; Kren L; Macak J; Smardova J
    J Clin Pathol; 2009 Oct; 62(10):948-50. PubMed ID: 19783727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma.
    Wlodarska I; Meeus P; Stul M; Thienpont L; Wouters E; Marcelis L; Demuynck H; Rummens JL; Madoe V; Hagemeijer A
    Leukemia; 2004 Oct; 18(10):1705-10. PubMed ID: 15306823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VH gene repertoire of mantle cell lymphomas.
    Varade W; Marin E; Milano M; Insel R; Swerdlow S; Williams M
    Ann N Y Acad Sci; 1995 Sep; 764():504-6. PubMed ID: 7486576
    [No Abstract]   [Full Text] [Related]  

  • 39. Characterization of 4 mantle cell lymphoma cell lines.
    Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
    Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
    Weinhold N; Johnson DC; Chubb D; Chen B; Försti A; Hosking FJ; Broderick P; Ma YP; Dobbins SE; Hose D; Walker BA; Davies FE; Kaiser MF; Li NL; Gregory WA; Jackson GH; Witzens-Harig M; Neben K; Hoffmann P; Nöthen MM; Mühleisen TW; Eisele L; Ross FM; Jauch A; Goldschmidt H; Houlston RS; Morgan GJ; Hemminki K
    Nat Genet; 2013 May; 45(5):522-525. PubMed ID: 23502783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.